Title and Organization:
Jung E. Choi, MBA, is chief business and strategy officer of Global Blood Therapeutics (GBT), a public biopharmaceutical company focused on creating innovative treatments that provide hope to underserved patient communities, including those with sickle cell disease. She leads business development, corporate and portfolio strategy, program leadership, patient advocacy, government affairs/policy. She has over 20 years of executive, transactional, and commercial leadership experience in the biopharmaceutical industry and has led or managed over 50 transactions exceeding $13 billion in value. She previously served as SVP, corporate development for InterMune during its acquisition and integration into Roche and Genentech, as well as SVP of corporate development for Chimerix. Jung held various management positions of increasing responsibility over nine years at Gilead Sciences, including head of business development, corporate strategy, mergers and acquisitions, and as director of marketing to commercially launch Hepsera. Prior to Gilead, Jung served as VP of Bay City Capital, and she started her career in strategy consulting at McKinsey & Company as an engagement manager. Jung serves on the Board of Annexon Biosciences, New York Blood Center, and is a founding leader of the GBT Equal Justice and Womens Groups. Jung holds a BA in human biology from Stanford University and an MBA from Stanford’s Graduate School of Business. Jung is a Fellow in the fifth class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.